Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. - Wikidata - awgldk - TriplyDB

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

http://www.wikidata.org/entity/Q33683115

about

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes The biased nucleotide composition of HIV-1 triggers type I interferon response and correlates with subtype D increased pathogenicity Clinical significance of HIV-1 coreceptor usage.HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis Profile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago Molecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western Kenya Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil HIV-1 Genetic Variability and Clinical Implications A national study of the molecular epidemiology of HIV-1 in Australia 2005-2012 Increased rate of CD4+ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore.Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden The influence of HIV-1 subtypes C, CRF31_BC and B on disease progression and initial virologic response to HAART in a Southern Brazilian cohort.Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.Effect of HIV-1 subtypes on disease progression in rural Uganda: a prospective clinical cohort study.Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.Deciphering the complex distribution of human immunodeficiency virus type 1 subtypes among different cohorts in Northern Tanzania.Evidence that HIV-1 CRF01_AE is associated with low CD4+T cell count and CXCR4 co-receptor usage in recently infected young men who have sex with men (MSM) in Shanghai, China.Genotypic prediction of HIV-1 subtype D tropism Frequencies of Gag-restricted T-cell escape "footprints" differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B alleles How Representative Are Research Tissue Biobanks of the Local Populations? Experience of the Infectious Diseases Biobank at King's College, London, UK Mechanisms and factors that influence high frequency retroviral recombination Analysis of a local HIV-1 epidemic in portugal highlights established transmission of non-B and non-G subtypes Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.HIV-1 Genetic Diversity and Its Impact on Baseline CD4+T Cells and Viral Loads among Recently Infected Men Who Have Sex with Men in Shanghai, China.Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women.Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides.Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.Drug resistance in antiretroviral-naive children newly diagnosed with HIV-1 in Manaus, Amazonas.

P2860

Q21245213-5C0F47DF-3F87-4B06-A1CA-69092E9FDF27 Q24498366-833EEB29-6530-44D6-ACC5-635790AE2DC9 Q27691426-73211775-8DF3-428F-8E6E-03A9FAB01BA4 Q28480877-0AC9AB49-7423-4047-9678-0B1EDE81CD17 Q28538242-DE9A5789-179D-4A63-B73C-D66DA4945799 Q28550140-CC0F99B6-B108-459A-AF9E-58AF1C29D9A3 Q28552354-F86A74E9-0D24-4C0C-BBF4-62C9CF967568 Q30352010-E58C1E37-FB16-45B9-82E8-D98DF9E35D5E Q33657146-B308EEBC-E143-4C44-8BF9-38BA1DABBF94 Q33813282-1876E32C-132E-49C5-B3B3-BC0DC2C423EA Q33850909-B3372ACC-C2FB-42E0-A9D7-16448EE82C63 Q33856712-E8DE9ABE-6FCB-4120-8288-DE77B9B4F332 Q33859741-6EFA4430-FCCD-4DAC-9A77-974C755A0B22 Q34145972-BA4AF311-9837-4F0C-A8A8-D377EB84B4D0 Q34741807-3F20DDBA-DBAA-4013-892B-AC3713873171 Q34923677-6045D6BB-3ECC-4670-93F3-0E1813240015 Q34950563-DF36558D-C825-4883-88FF-03A34D04949B Q35036284-FBB50660-8705-49E7-BFB8-476317C117A5 Q35069814-B33B6BB7-3D3B-45E2-BE2F-07363DD548C9 Q35107377-FCFADE36-0872-4094-9C2B-657C6AF84ACF Q35137552-980C723B-01C5-4180-A235-CA823D2158DF Q35219461-FBC166CD-4F95-463B-A3A7-952EF3380FE8 Q35227422-2D3092AF-3727-4C45-96F9-BF6C4EBD9709 Q35276750-884E4031-338D-432F-869F-DC5F7A7D9FE5 Q35455551-7F7AA0DE-6998-4C76-8387-216D8D90801C Q35508265-DA613D33-A607-4829-8E3F-6DA37EBF61B5 Q35588149-92C40C54-C769-41B4-9F17-A66BB5CAC905 Q35677338-F077EF72-5E87-40EB-ACDE-78B309B317B9 Q35763306-B029A275-F1C0-4029-83B1-B43BD5322C63 Q35827900-A1DAAD2F-6973-44E7-B608-3640B16FE32D Q35880435-F23D50F0-B9DD-4BC9-BD66-CE3939413ACB Q36272864-34A095EB-33A3-4AA5-A3C4-762CC7E23534 Q36458517-781BBB3C-BBE2-4901-8D82-A2BA0FA3475B Q36558495-2EC2749A-3700-43F0-802F-71510E0ABFC7 Q37108384-4684F262-14AE-4698-9150-0AB5E07829A4 Q37660267-30CCAC0D-61BB-48EC-A91C-7E3271822567 Q37859395-A4AC9351-8835-4850-8AA4-EAAA07089217 Q38208721-B1135D5F-364F-427F-8DC4-E6FEF6F2CBB2 Q38706845-4490CF22-79F4-4300-A4DF-38B9EA0C7D0D Q38875150-E509E253-8FC7-4C50-A1D9-B8DA812AA8ED

P2860

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

http://www.wikidata.org/entity/Q33683115

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@ast

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@en

type

label

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@ast

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@en

prefLabel

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@ast

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@en

P1433

Q33683115-9863E8D5-BF63-481A-9E97-F39B9EEE9536

P1476

Q33683115-BA73BC9F-5AF1-4EA0-874C-B5085F66F744

P2093

Q33683115-244860C9-B272-44B4-9F9C-2AA4BB11C1C4

Q33683115-51D5903C-C291-4C4F-B7DD-64D17C0F3991

Q33683115-618C33B0-DABC-400B-AFA1-0A926C5B6037

Q33683115-7AF79B79-D6EA-4B2E-A649-8CF918DAB71D

Q33683115-9C4467AB-F52B-4780-A28D-FE87C68C8E78

Q33683115-B2087CE9-2634-4A83-AACF-4A1FC31E0D2C

Q33683115-CC071A26-6434-4E0B-94C0-BD368ACC0C89

Q33683115-D08FDA66-E8FE-471E-B1F0-C00A1E7ADA3A

Q33683115-DCCC4E6F-92CA-44A9-800F-9C04A6E3705F

P2860

Q33683115-01814704-E943-4C53-947E-0A30E26B1099

Q33683115-02CF2984-9850-45DB-8EB9-BF2E63256FF4

Q33683115-03BD4996-4872-4728-9735-5771E9B409C2

Q33683115-0AE8A1F9-27A3-476A-9D4F-FFA87A2ECA71

Q33683115-0C9A3B48-322D-4037-ACF8-D67AF9E057F3

Q33683115-0E6C66DE-33CD-44D6-B89D-0AF6115801F8

Q33683115-13D9AFF7-CFF0-4BC0-BDB6-7BB5B379E8B2

Q33683115-1DDF4266-8572-49E8-9FA5-97DADCB4DD2E

Q33683115-2513C079-EA52-40F9-BA24-BDA8002E1E2B

Q33683115-2E35CE68-111A-4535-9DA5-1D793D4CC7B8

P2888

Q33683115-762455F3-DEC5-4CE0-B241-1C9A219F908F

P304

Q33683115-0F8F271B-C6BB-4CC7-BB2B-88AF9B887FCC

P31

Q33683115-EA47E24A-C0CA-4925-BB7E-B7912924D918

P356

Q33683115-3AAEB62F-3240-4067-9F1A-6835DC96FDB9

P478

Q33683115-753FDD57-3E14-4D42-BBB2-10B6D66D94A5

P577

Q33683115-66B7FD22-2A11-4DAC-A377-B42734D1FA01

P5875

Q33683115-6D43FD56-4820-42EF-B7FB-E5134CA52EAE

P6179

Q33683115-520C322E-6047-4CF5-8477-570FCC176510

P698

Q33683115-4818AD04-CEB2-445E-8C68-615E5778B392

P921

Q33683115-436EC535-DA73-4A9E-A927-1EB37B0EA906

Q33683115-B73BE9A4-D21F-4143-A055-43DE11FE5DC4

P932

Q33683115-064C52A2-EEEF-463B-813E-0B727C68F5A6

P356

P1433

Journal of the International AIDS Society

P1476

Impact of HIV-1 viral subtype ...... nse to antiretroviral therapy.

@en

P2093

Anna Maria Geretti

http://www.w3.org/2001/XMLSchema#string

Annemiek de Ruiter

http://www.w3.org/2001/XMLSchema#string

Iain D Tatt

http://www.w3.org/2001/XMLSchema#string

Ian Chrystie

http://www.w3.org/2001/XMLSchema#string

Jane Mullen

http://www.w3.org/2001/XMLSchema#string

Mark Zuckerman

http://www.w3.org/2001/XMLSchema#string

Mel Smith

http://www.w3.org/2001/XMLSchema#string

Philippa J Easterbrook

http://www.w3.org/2001/XMLSchema#string

Siobhan O'Shea

http://www.w3.org/2001/XMLSchema#string

P2860

Estimated Global Distribution and Regional Spread of HIV-1 Genetic Subtypes in the Year 2000

Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda

Human immunodeficiency virus type 1 subtypes differ in disease progression

Rapid and simple method for purification of nucleic acids

Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries.

Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy.

Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants.

Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: correlation with genotyping.

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance.

Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London.

P2888

P304

4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1758-2652-13-4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41806537

http://www.w3.org/2001/XMLSchema#string

P6179

1031446293

http://www.w3.org/2001/XMLSchema#string

P698

20205896

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2827379

http://www.w3.org/2001/XMLSchema#string